| 0 (0%) | 09-27 09:32 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 76.26  |
1-year : | 77.46 |
| Resists | First : | 65.29 |
Second : | 66.31 |
| Pivot price | 65.46 |
|||
| Supports | First : | 63.63 |
Second : | 52.94 |
| MAs | MA(5) : | 65.1 |
MA(20) : | 65.27 |
| MA(100) : | 64.5 |
MA(250) : | 63.81 |
|
| MACD | MACD : | 0.1 |
Signal : | 0.2 |
| %K %D | K(14,3) : | 19.7 |
D(3) : | 33.2 |
| RSI | RSI(14): 46.6 |
|||
| 52-week | High : | 68.77 | Low : | 58.9 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ FXA ] has closed above bottom band by 14.1%. Bollinger Bands are 7.2% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 64.92 - 65.31 | 65.31 - 65.69 |
| Low: | 63.7 - 64.17 | 64.17 - 64.62 |
| Close: | 64.17 - 64.86 | 64.86 - 65.51 |
Thu, 25 Sep 2025
VarmX receives Phase 1 waiver from Japanese regulator PMDA for lead asset VMX-C001 - GlobeNewswire
Fri, 05 Sep 2025
BT arrests viral replication in an FXa independent manner. (A)... - researchgate.net
Sun, 20 Jul 2025
Significance of FXa and its receptor PAR2 for the growth of colon cancer cells in vitro and in vivo - Frontiers
Tue, 08 Jul 2025
VarmX secures US approval to begin phase 3 trial of urgent surgery treatment - PharmaTimes
Wed, 04 Jun 2025
Have a Ball at These 6 Northern Virginia Adult Sports Leagues - Northern Virginia Magazine
Wed, 09 Apr 2025
Bayer’s BAY-3389934 allows optimal controllability in sepsis-induced coagulopathy treatment - BioWorld MedTech
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|